Rare Disease Program
Undisclosed Rare Disease
DiscoveryActive
Key Facts
About PeptiDream
PeptiDream's mission is to revolutionize drug discovery by developing macrocyclic peptides as a new therapeutic modality to address undruggable targets. The company has achieved remarkable success through its proprietary PDPS technology, securing high-value partnerships with nearly every major global pharmaceutical firm. Its strategy combines a capital-efficient platform business with the advancement of a proprietary pipeline, particularly in oncology and infectious diseases. This dual approach has generated significant revenue and driven its valuation to over $150 billion, positioning it as a dominant force in the peptide therapeutics space.
View full company profileOther Undisclosed Rare Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| AX-0810 | ProQR Therapeutics | Pre-clinical/Phase 1 |